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De novo lipogenesis in adipocytes, especially with
high fat feeding, is poorly understood. We demon-
strate that an adipocyte lipogenic pathway encom-
passing fatty acid synthase (FAS) and PexRAP
(peroxisomal reductase activating PPARg) modu-
lates endogenous PPARg activation and adiposity.
Mice lacking FAS in adult adipose tissue manifested
increased energy expenditure, increased brown fat-
like adipocytes in subcutaneous adipose tissue,
and resistance to diet-induced obesity. FAS knock-
down in embryonic fibroblasts decreased PPARg
transcriptional activity and adipogenesis. FAS-
dependent alkyl ether phosphatidylcholine species
were associated with PPARg and treatment of
3T3-L1 cells with one such ether lipid increased
PPARg transcriptional activity. PexRAP, a protein
required for alkyl ether lipid synthesis, was associ-
ated with peroxisomes and induced during adi-
pogenesis. PexRAP knockdown in cells decreased
PPARg transcriptional activity and adipogenesis.
PexRAPknockdown inmicedecreasedexpressionof
PPARg-dependent genes and reduced diet-induced
adiposity. These findings suggest that inhibiting
PexRAP or related lipogenic enzymes could treat
obesity and diabetes.
INTRODUCTION
A relentless increase in mean global body weight since 1980
has resulted in an estimated 1.5 billion overweight people world-
wide, of which a half billion are obese (Finucane et al., 2011).
Obesity leads to diabetes, which is associated with premature
death from many causes (Seshasai et al., 2011). Obesity is
caused by positive energy balance leading to expansion of
adipocyte mass. However, adipocytes possess functional path-
ways that might be targeted to complement therapies altering
energy balance. De novo lipogenesis, an adipocyte functionCelthat requires the multifunctional enzyme fatty acid synthase
(FAS) (Semenkovich, 1997), is one such potential target since
adipose tissue FAS has been implicated in obesity and insulin
resistance in humans (Moreno-Navarrete et al., 2009; Roberts
et al., 2009; Schleinitz et al., 2010).
Fatty acid synthase catalyzes the first committed step in
de novo lipogenesis. The magnitude of de novo lipogenesis is
different in rodents and people. Lipogenesis is thought to be
a relatively minor contributor to whole body lipid stores in
a present-day human consuming a typical high fat diet (Aarsland
et al., 1996; Letexier et al., 2003; McDevitt et al., 2001). However,
pharmacologic or genetic manipulation of enzymes in the lipo-
genic pathway can have profound metabolic consequences
(Postic and Girard, 2008), suggesting that de novo lipogenesis
might serve a signaling function independent of the generation
of lipid stores (Lodhi et al., 2011). Consistent with this concept,
FAS in liver is part of a lipogenic pathway involved in the gener-
ation of a ligand for peroxisome proliferator-activated receptor
a (PPARa) (Chakravarthy et al., 2009), a key transcriptional regu-
lator of fatty acid oxidation.
PPARs, consisting of PPARa, PPARd and PPARg, are ligand
activated transcription factors that form obligate heterodimers
with the retinoid X receptor (RXR) and regulate metabolism
(Wang, 2010). Ligand binding results in a conformational change
in the receptor, promoting dissociation of repressors, recruit-
ment of coactivators, and subsequent activation of target gene
expression. This nuclear receptor family was identified and
named based on activation by chemicals that promote prolifera-
tion of peroxisomes (Dreyer et al., 1992; Issemann and Green,
1990).
Peroxisomes participate in the oxidation of certain fatty acids
as well as the synthesis of bile acids and ether lipids (Wanders
and Waterham, 2006). These single membrane-enclosed organ-
elles are present in virtually all eukaryotic cells. In adipocytes
they tend to be small and were referred to as microperoxisomes
by Novikoff and colleagues, who documented a large increase in
peroxisome number during the differentiation of 3T3-L1 adipo-
cytes (Novikoff and Novikoff, 1982; Novikoff et al., 1980).
We sought to evaluate the role of de novo lipogenesis in adipo-
cyte function and metabolism. Here we show that a lipogenic
pathway encompassing FAS and PexRAP (peroxisomal reduc-
tase activating PPARg), an enzyme localized to peroxisomesl Metabolism 16, 189–201, August 8, 2012 ª2012 Elsevier Inc. 189
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Figure 1. Targeted Deletion of Adipose Tissue FAS Decreases Adiposity
(A) FAS protein by western blot in brown (BAT) and white (WAT) adipose tissue of Lox/Lox control (without Cre), adiponectin-Cre control (without floxed alleles),
and FASKOF mice.
(B) Tissue distribution of FAS protein by western blot. An apparent increased expression of hepatic FAS protein in FASKOF mice was not consistently observed.
(C) FAS enzyme activity assay. *p = 0.031. N = 4/genotype.
(D) Body weight of HFD-fed control and FASKOF male mice. Similar results were also obtained in two additional feeding experiments with different cohorts of
male mice. *p = 0.03. **p = 0.0068 at 16 weeks, 0.0028 at 20 weeks. N = 6-8/genotype. Additional data including females are provided in Table S1.
(E) MRI analysis of body composition in HFD-fed mice. **p < 0.0001. N = 6/genotype.
(F) Tissue weights of HFD-fed control and FASKOF mice. **p = 0.005. N = 6/genotype.
(G) Histologic appearance of WAT harvested from chow-fed or HFD-fed mice.
(H) Adipocyte size distribution determined with the NIH Image J program. Error bars in (C)–(F) represent SEM.
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Lipogenesis and Adipose Programmingand encoded by a previously unidentified mammalian gene,
contributes to the endogenous activation of PPARg and modu-
lates adiposity with high fat feeding.
RESULTS
Targeted Deletion of Adipose Tissue FAS
We generated FAS knocked out in fat (FASKOF) mice by
crossing FASlox/lox mice (Chakravarthy et al., 2005) with adipo-
nectin-Cre transgenic mice (Eguchi et al., 2011). FASKOF
mice, born at the expected Mendelian frequency, were overtly
normal. FAS protein was decreased in white and brown adipose
tissue of FASKOF relative to Cre only (without lox sites) and lox/
lox (without Cre) control mice (Figures 1A and 1B). FAS protein
content was not decreased in whole brain extracts of FASKOF190 Cell Metabolism 16, 189–201, August 8, 2012 ª2012 Elsevier Incmice (Figure 1B). FAS mRNA assayed by quantitative RT-PCR
was the same in the hypothalamus of FASKOF and lox/lox
mice (not shown), suggesting that phenotypes are not likely to
be due to CNS effects (Lu et al., 2011; Ryan et al., 2011). FAS
enzyme activity was decreased in fat but not liver of FASKOF
mice (Figure 1C). Hepatic FAS enzyme activity was not signifi-
cantly increased in the setting of decreased adipose tissue
FAS activity (Figure 1C).
Chow-fed FASKOF and control mice weighed the same.
However, feeding a high fat diet (HFD) elicited a phenotypic
difference. HFD-fed FASKOF mice weighed less (Figure 1D)
and had less adiposity as well as more lean tissue compared
to controls (Figure 1E). The adiposity effect was seen in both
sexes and also in the setting of high carbohydrate/zero fat diet
feeding (Table S1). Epididymal fat pads (white adipose tissue,.
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Lipogenesis and Adipose ProgrammingWAT), but not other tissues, from HFD-fed FASKOF mice
weighed less than those from control mice (Figure 1F). White
adipocytes isolated from FASKOFmicewere smaller than adipo-
cytes from control mice with HFD feeding (Figures 1G and 1H),
but there was no effect with chow feeding. Genotype and diet
had no effect on adipocyte cell number (not shown), perhaps
reflecting induction of adiponectin-Cre expression following adi-
pose tissue development.
The weight of brown adipose tissue (BAT) was not different in
mice fed HFD. However, when adult mice were fed a high carbo-
hydrate/zero fat diet, which maximizes effects due to FAS defi-
ciency, the BAT depot in FASKOF mice weighed significantly
less than that of control mice (Figure S1A). The histologic
appearance of BAT was not different between genotypes in
mice fed HFD, but lipid stores were depleted (Figure S1B) and
the PPARg target genes CD36, HSL, and ATGL were decreased
(Figure S1C) in the BAT depot from FASKOF mice fed a high
carbohydrate/zero fat diet.
Hepatic histologic appearance (Figure S1D) and lipid content
(Figure S1E) were not different between control and FASKOF
animals.
Altered Thermogenesis in FASKOF Mice
Food intake was not different between FASKOF and control
mice on any diet (Table S1). When studied on a HFD prior to de-
velopment of statistically significant differences in body weight,
FASKOF mice had increased energy expenditure compared to
controls (Figure 2A). Systemic glucose tolerance and insulin
sensitivity were enhanced in HFD-fed FASKOF mice (notable
for less adiposity) compared to controls (Figures 2B and 2C),
but with chow feeding (a condition associated with similar
degrees of adiposity in each genotype) there was no difference
in glucose tolerance between FASKOF and control mice (Fig-
ure S1F). Consistent with the observation that decreased
adiposity improves insulin sensitivity in numerous animal models
(Elchebly et al., 1999; Masuzaki et al., 2001; Yang et al., 2005;
Yuan et al., 2001), levels of phospho-Akt relative to total Akt
were increased in skeletal muscle of HFD-fed FASKOF mice
(data not shown). Serum leptin was lower (perhaps reflecting
decreased adiposity) but adiponectin was unaffected in HFD-
fed FASKOF mice (Table S1). Given effects of FAS deletion on
other PPARg genes (see below), it is possible that not all targets
of PPARg, including adiponectin, are affected by FAS deletion.
Monitored physical activity was not increased in FASKOF ani-
mals (Figure S1G).
Body temperature was not different between control and
FASKOF mice at room temperature, there were no apparent
brown fat-like adipocytes in the epididymal fat of FASKOF
mice, and FASKOF epididymal fat did not have increased
expression of the brown fat gene UCP1 (not shown). However,
UCP1 expression was strikingly increased in inguinal fat from
HFD-fed FASKOF mice as compared to controls (Figure 2D).
Expression of PRDM16, a transcriptional coregulator involved
in the development of classic BAT as well as brown fat-like
adipocytes in subcutaneous white adipose tissue (WAT) (Seale
et al., 2011), was also increased as were levels of the brown
fat genes Cidea and PGC1a (Figure 2D). PPARa is known to
induce UCP1 expression (Barbera et al., 2001), andmRNA levels
for PPARa as well as the PPARa-dependent genes CPT1 andCelACO were increased in inguinal fat (Figure 2D). Since PPARa
promotes fatty acid oxidation, we assayed this process in
homogenates of WAT as the release of CO2 from radiolabelled
palmitate. In HFD-fed mice, fatty acid oxidation was increased
in FASKOF as compared to control mice in inguinal but not
epididymal WAT (Figure 2E). To maximize effects due to
FAS deficiency, we fed mice a high carbohydrate/zero fat diet
and analyzed inguinal fat. Under these conditions, inguinal fat
mRNA levels for UCP1, Cidea, and PGC1a were increased (Fig-
ure S1H). UCP1 protein was increased in inguinal fat from
FASKOF as compared to control mice by both western blotting
(Figure 2F) and immunocytochemistry (Figure 2G). With cold
exposure, FASKOF mice maintained their body temperature at
a significantly higher level than controlmice (Figure 2H), suggest-
ing that increased brown fat-like cells in subcutaneous WAT of
FASKOF are physiologically relevant.
FAS Promotes PPARg Activation and Adipogenesis
PPARg is necessary and sufficient for adipogenesis (Tontonoz
and Spiegelman, 2008) but also mediates HFD-induced hyper-
trophy of adipocytes (Hosooka et al., 2008; Kubota et al., 1999).
Moreover, PPARg is thought to promote fat development at
the expense of myogenesis (Hu et al., 1995; Seale et al., 2008).
Previous studies suggested that lipogenic pathways may be
required for activating PPARg by generating its endogenous
ligand (Kim and Spiegelman, 1996; Kim et al., 1998) and influ-
encing adipogenesis (Schmid et al., 2005).
Since HFD-fed FASKOF mice have decreased adiposity and
reduced adipocyte hypertrophy (Figure 1), we explored the pos-
sibility that FAS is involved in PPARg activation and adipogene-
sis using mouse embryonic fibroblasts (MEFs) from FASlox/lox
animals. Expression of Cre using an adenovirus (Ad-Cre) in these
cells decreased FAS protein and impaired adipogenesis (Figures
3A and 3B). Defective adipogenesis induced by FAS deficiency
was rescued by treatment with the PPARg activator rosiglitazone
(Figure 3B, bottom panels), likely due to induction of processes
(involving CD36, LPL, and other proteins) that facilitate uptake
of lipids from the culture media.
We next transfected HEK293 cells with cDNAs for PPARg
and a PPAR-dependent luciferase reporter in the presence
or absence of FAS knockdown. FAS deficiency decreased
luciferase reporter activity, an effect that was rescued with
rosiglitazone, suggesting that FAS regulates PPARg transcrip-
tional activity (Figure 3C). To address possible contributions of
ligand-independent effects of FAS knockdown on PPARg trans-
activation, we performed luciferase reporter assays using cells
transfected with constitutively active PPARg (VP16-PPARg) or
wild-type PPARg. FAS knockdown reduced luciferase reporter
activity in cells transfected with WT PPARg, and the effect was
significantly greater than in cells transfected with VP16-PPARg
(Figure 3D). Knockdown of FAS in primary MEFs decreased
expression of the PPARg target genes aP2 and CD36 but
increased expression of the early myogenesis markers MyoD
andmyogenin, effects that were reversed with rosiglitazone (Fig-
ure 3E). Consistent with induction of myogenic markers, FAS
inactivation was associated with myotube formation under
promyogenic culture conditions (Figure 3F). FAS knockdown
decreased levels of proteins regulated by PPARg in 3T3-L1
adipocytes (Figure 3G). PPARg target gene expression wasl Metabolism 16, 189–201, August 8, 2012 ª2012 Elsevier Inc. 191
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Figure 2. Altered Metabolism in Mice with Adipose-Specific Knockout of FAS
(A) Oxygen consumption (VO2) by indirect calorimetry in HFD-fed mice. Indicated p value by ANOVA. N = 8–10/genotype.
(B) Glucose tolerance testing in HFD-fed mice. p = 0.0477 at 0 min, 0.0415 at 60 min. N = 6–8/genotype. Serum insulin values at 30 min point shown in the inset.
(C) Insulin tolerance testing in the mice of (B). *p = 0.039.
(D) RT-PCR analysis of gene expression in inguinal WAT of HFD-fed control and FASKOFmalemice. Gene expression analysis in inguinalWAT of ZFD-fedmice is
presented in Figure S1H. **p = < 0.0001 for UCP1, 0.0017 for Cidea, 0.0001 for PRDM16, 0.0008 for PGC1a, 0.0012 for PPARa, and 0.0001 for CPT1; *p = 0.042
for ACO.
(E) Measurement of fatty acid oxidation in epididymal (eWAT) and inguinal (iWAT) fat of control and FASKOF mice fed HFD. *p = 0.0355 for HFD iWAT. N = 3
animals/genotype for each diet.
(F) Western blot analysis in inguinal WAT of ZFD-fed control and FASKOF male mice. Each lane represents a separate mouse.
(G) Immunocytochemical analysis of UCP1 expression in inguinal WAT of ZFD-fed control and FASKOF mice. Images are from two separate mice per genotype.
(H) Rectal temperature of ZFD-fed control and FASKOF mice at room temperature (23C) and after 1 hr exposure to 4C. N = 6–8 animals/genotype. *p = 0.011.
Error bars in (A)–(E) and (H) represent SEM.
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Lipogenesis and Adipose Programmingrestored in these murine cells with FAS knockdown by express-
ing human FAS (Figure 3H). PPARg target genes were also
decreased in the adipose tissue of FASKOF mice (Figure 3I).
To determine if FAS deficiency is affecting PPARg expression
as opposed to its transcriptional activity, we fed mice a high
carbohydrate/zero fat diet to maximize effects due to FAS defi-
ciency and subjected gonadal WAT to western blotting. There
was no effect on PPARg protein mass while protein levels of
the PPARg target aP2 were decreased in FASKOF as compared
to control mice (Figure 3J). One plausible interpretation of these192 Cell Metabolism 16, 189–201, August 8, 2012 ª2012 Elsevier Incresults is that FAS is part of a lipogenic pathway that regulates
adipogenesis at the expense of myogenesis by generating
endogenous ligands for PPARg that promote its transcriptional
activity.
Identification of FAS-Dependent Diacyl and Alkyl Ether
Lipid Species Bound to PPARg
There are probably numerous PPARg endogenous ligands that
may be generated under conditions requiring alterations in
adipocyte function, but ligands are initially produced early during.
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Figure 3. FAS Is Required for Adipogenesis and PPARg Activation
(A) Western blot analysis of FAS knockdown in primaryMEFs from FASlox/lox mice treatedwith an adenovirus expressing GFP or Cre at the indicatedmultiplicity of
infection (moi).
(B) Oil red O staining of FASlox/lox MEFs treated with Ad-GFP or Ad-Cre and differentiated to adipocytes in the presence or absence of rosiglitazone.
(C) HEK293 cells treated with control or FAS siRNA were transfected with plasmids encoding PPRE-luciferase, Renilla luciferase and wild-type PPARg in the
presence or absence of rosiglitazone. **p < 0.0001 versus control, #p < 0.0001 versus FAS siRNA basal. N = 3/condition.
(D) HEK293 cells treated with control or FAS siRNA were transfected with plasmids encoding PPRE-luciferase, Renilla luciferase and wild-type PPARg or VP16-
PPARg DBD (an N-terminal fragment of PPARg encompassing the DNA binding domain fused to the VP16 transactivation domain). **p < 0.0001 versus control,
#p < 0.0001 versus FAS siRNA/WT PPARg. N = 3/condition.
(E) RT-PCR analysis of gene expression in FAS-deficient (Ad-Cre-treated) or control (Ad-GFP-treated)MEFs subjected to the adipogenesis protocol. **versus Ad-
GFP, p = 0.0060 for aP2, 0.0010 for CD36, 0.0051 for MyoD, 0.0007 for Myogenin. #versus Ad-Cre, p = 0.0015 for aP2, 0.0013 for CD36, 0.0099 for MyoD, 0.0019
for Myogenin.
(F) FAS-deficient (Ad-Cre-treated) or control (Ad-GFP-treated) MEFs cultured to promote myogenesis and stained with a skeletal muscle myosin heavy chain
antibody.
(G) Detection of proteins induced by PPARg in 3T3-L1 fibroblasts and adipocytes treated with control or FAS shRNA.
(H) Restoration of PPARg target gene expression with human FAS using 3T3-L1 adipocytes with endogenous knockdown of FAS. 3T3-L1 cells stably expressing
retrovirally encoded human FAS were infected with a lentivirus expressing scrambled control (SC) or mouse FAS shRNA. The cells were induced to differentiate
into adipocytes. The upper panel shows real-time PCR analysis of aP2 expression and the bottom panel shows a western blot with antibodies against FAS, HA,
and actin. *p = 0.0224 (versus SC shRNA, empty vector). #p < 0.0001 (versus FAS shRNA, empty vector).
(I) RT-PCR analysis of gene expression in control and FASKOF gonadal WAT. **p = 0.007. *p = 0.0493 for C/EBPa, 0.010 for LPL, 0.039 for CD36. N = 4/genotype.
(J) Western blot analysis in gonadal WAT of ZFD-fed control and FASKOF female mice. Each lane represents a separate mouse. Error bars in (C)–(E), (H), and (I)
represent SEM.
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Lipogenesis and Adipose Programmingadipocyte differentiation (Tzameli et al., 2004). To isolate such
putative FAS-dependent ligands, we used mass spectrometry
after infecting MEFs with an adenovirus encoding FLAG-tagged
PPARg and inducing differentiation (Figure 4A). PPARg was iso-Cellated by affinity from cells in the presence or absence of FAS
knockdown (Figure 4B) and associated lipids were analyzed by
mass spectrometry (Figure 4C). We identified several phospha-
tidylcholine species with diacyl (ester bond-linked) or 1-O-alkyll Metabolism 16, 189–201, August 8, 2012 ª2012 Elsevier Inc. 193
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Figure 4. Isolation of FAS-Dependent Diacyl and 1-O-alkyl Ether Phosphatidylcholine Species Associated with PPARg
(A) Strategy for detection of PPARg-associated lipids.
(B) Detection of FLAG-PPARg protein immunoprecipitated from adipocytes treated with control or FAS shRNA.
(C) Mass spectrometric analyses of [M+Li]+ ions of glycerophosphocholine (GPC) lipids bound to FLAG-PPARg or control protein (GFP) immunoprecipitated from
control and FAS knockdown adipocytes. Ions of m/z 752 and 780 represent 1-O-alkyl GPC species.
(D) CV-1 cells were transfected with plasmids encoding UAS-luciferase, Renilla luciferase and Gal4-PPARg LBD (a C-terminal fragment of PPARg encompassing
the ligand binding domain fused to the Gal4 DNA binding domain) or Gal4 alone. The cells were treated with 18:1e/16:0-GPC (corresponding to m/z 752 in C),
rosiglitazone, or DMSO. After 48 hr, UAS-luciferase reporter activity was measured and normalized to Renilla luciferase reporter activity. **p = 0.0001. *p = 0.018
(10 mM), 0.024 (20 mM), 0.019 (80 mM).
(E) 3T3-L1 cells were induced to differentiate in DMEM+10%FBSwith supplemental dexamethasone, insulin and IBMX in the presence of 20 mM18:1e/16:0-GPC
or DMSO. After 3 days, the cells were retreated with the GPC in media containing supplemental insulin alone. The next day, the cells were harvested for RNA
extraction and real-time PCR analysis. The data are representative of 3 separate experiments. *p = 0.0147 (aP2), 0.0006 (LPL), 0.0102 (CD36). Error bars in (D) and
(E) represent SEM.
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Lipogenesis and Adipose Programming(ether bond-linked) side chains associated with PPARg that were
competitively displaced by rosiglitazone (not shown). Alkyl ether
lipids were particularly enriched in PPARg samples compared to
controls (Table S2). The species at m/z 752 [M+Li]+ was most
frequently associated with PPARg and tandem mass spectrom-
etry identified it as 1-O-octadecenyl-2-palmitoyl-3-glycerophos-
phocholine (18:1e/16:0-GPC) (Figure S2). We synthesized this
alkyl ether lipid and used it to treat cultured cells. 18:1e/16:0-
GPC increased PPARg-dependent luciferase reporter activity194 Cell Metabolism 16, 189–201, August 8, 2012 ª2012 Elsevier Incin a dose-dependent fashion (Figure 4D) but was less potent
than rosiglitazone. We found that 20 mM 18:1e/16:0-GPC signif-
icantly increased the expression of PPARg target genes in differ-
entiating 3T3-L1 adipocytes (Figure 4E).
In order to provide insight into the interaction between
18:1e/16:0-GPC and the PPARg ligand binding domain (LBD),
we developed a GST-pulldown assay of PPARg ligand bind-
ing based on the ligand-dependent interaction between an
N-terminal region of CBP1 and the PPARg LBD (Gelman et al.,.
Cell Metabolism
Lipogenesis and Adipose Programming1999). 18:1e/16:0-GPC increased the interaction between the
GST-tagged PPARg LBD and the myc-tagged CBP1 N terminus
in a dose-dependent manner (Figure S3A). However, 18:1e/16:0-
GPC did not increase the interaction between the GST-tagged
LBD of a different nuclear receptor, PPARa, and the myc-tagged
CBP1 N terminus (Figure S3B). To provide additional evidence
that this ether lipid enhances PPARg transcription due to ago-
nism, we added 18:1e/16:0-GPC to terminally differentiated
3T3-L1 adipocytes. Both 18:1e/16:0-GPC and rosiglitazone
increased LPL gene expression in differentiated adipocytes
that were treatedwith a control shRNAprior to induction of differ-
entiation (Figure S3C). In cells prevented from differentiating into
adipocytes by FAS knockdown, treatment with either 18:1e/
16:0-GPC or rosiglitazone after completion of the differentiation
protocol (with dexamethasone, IBMX, and insulin followed by
additional insulin treatment) did not restore full LPL expression
(Figure S3C). FAS deficiency decreased expression of PPARg-
dependent genes (Figure 3I) while increasing expression of
PPARa-dependent genes (Figure 2D). When FAS expression
was knocked down in 3T3-L1 cells that were subsequently
induced to differentiate into adipocytes, the FAS-deficiency-
associated increase in ACO gene expression was significantly
decreased when cells were differentiated in the presence of
the selective PPARa antagonist GW6471 (Figure S3D). These
results suggest that an FAS-dependent ether lipid interacts
with PPARg but not PPARa and that FAS deficiency is associ-
ated with decreased activation of PPARg and increased activa-
tion of PPARa.
Cloning and Characterization of PexRAP
Ether lipid synthesis in mammals occurs through the peroxi-
somal acyl dihydroxyacetone phosphate (DHAP) pathway, al-
lowing synthesis of lysophosphatidic acid as an alternative to
direct acylation of glycerol 3-phosphate. This pathway is obliga-
tory for synthesis of ether lipids including platelet activating
factors and plasmalogens (Hajra and Das, 1996; Hajra et al.,
2000; McIntyre et al., 2008) (Figure 5A). The terminal enzyme
activity in this pathway, acyl/alkyl DHAP reductase, was purified
and characterized from guinea pig liver (LaBelle and Hajra,
1974), but the gene encoding this protein has not been identified
inmammals (McIntyre et al., 2008). Since a yeast enzyme (Ayr1p)
(Athenstaedt and Daum, 2000) that catalyzes this reaction has
been cloned and characterized, we used this sequence to iden-
tify DHRS7b, a protein of unknown function, as a mammalian or-
tholog (Figure 5B). We renamed this protein PexRAP. Gradient
fractionation of 3T3-L1 adipocytes showed that PexRAP is
enriched in fractions containing peroxisomal markers, such as
PMP70 and catalase (Figure 5C). Myc-tagged PexRAP coimmu-
noprecipitated with Pex19 (peroxisomal biogenesis factor 19, an
import receptor for peroxisomal membrane proteins) (Figure 5D),
and this interaction was confirmed in pulldown experiments
using GST-PexRAP (Figure 5E).
To demonstrate that PexRAP mediates its predicted enzyme
activity, we knocked down PexRAP expression in MEFs (Fig-
ure 5F) and found decreased levels of 1-O-alkyl ether phospho-
lipids as well as certain diacyl phospholipids (Figure 5G), some of
which also arise from the DHAP pathway. 18:1e/16:0-GPC was
detected in these experiments as m/z 746 [M+H]+ since these
experiments were performed with protonated species; 18:1e/Cel16:0-GPC was detected as m/z 752 using lithiated species in
Figure 4C. PexRAP protein was detected in multiple tissues,
but levels were low in skeletal muscle (Figure 5H). The overall
expression of PexRAP in BAT was relatively low and BAT
primarily expressed a shorter isoform (which lacks 9 amino
acid residues at the N terminus), suggesting that PexRAP may
have a different role in BAT compared to WAT. Both PexRAP
and FAS proteins markedly increase early during differentia-
tion of 3T3-L1 adipocytes, prior to similar increases in proteins
such as C/EBPa and aP2 known to be induced by PPARg acti-
vation (Figure 5I). Thus, PexRAP is peroxisomal, its inactivation
decreases lipids associated with PPARg, and its temporal rela-
tionship during differentiation with other adipocyte proteins
suggests that it could be involved in adipogenesis.
PexRAP Is Required for Adipogenesis
To address the role of PexRAP in adipogenesis, we knocked
down its expression in 3T3-L1 cells. Adipogenesis (assessed
by both Nile red staining and triglyceride content) was abro-
gated with PexRAP knockdown and rescued with rosiglitazone
(Figures 6A and 6B), suggesting that PexRAP, like FAS (Fig-
ure 3B), affects PPARg activation. Knockdown of PexRAP or
DHAP acyltransferase (DHAPAT, the enzyme immediately up-
stream of PexRAP, Figure 5A) in 3T3-L1 adipocytes decreased
expression of PPARg target genes (Figure 6C). Rosiglitazone
treatment rescued the effect of PexRAP or DHAPAT knockdown
on PPARg target genes (Figure 6D).
PexRAP Knockdown in Mice Alters Body Composition
and Metabolism
We translated these observations to HFD-fed C57BL/6J mice,
characterized by increased adiposity and insulin resistance.
A series of PexRAP antisense oligonucleotides (ASOs) were
screened for effectiveness (not shown) and results of PexRAP
knockdown for two of themost promising are shown in Figure 7A
using Hepa1-6 cells. ASO2 was selected for use in mice. Intra-
peritoneal administration of ASO2 at up to 20 mg/kg twice
a week for three weeks resulted in a dose-dependent decrease
in PexRAP protein in WAT and liver (but not in brain or skeletal
muscle, Figures 7B and S4A). Mice were fed a HFD for four
weeks to increase adiposity and then animals were injected
twice a week with 20 mg/kg of ASO2 or the control ASO for
24 days while HFD was continued. ASO treatment had no
effect on liver function tests or liver histology (not shown). Liver
fat content was nearly significantly lower (p = 0.072) with ASO
treatment. Food intake was unaffected (Table S3). However,
this intervention decreased expression of PexRAP as well as
PPARg target genes (including PPARg itself) in WAT (Figure 7C).
PexRAP knockdown in HFD-fed mice also decreased adiposity,
increased leanness, and decreased fasting glucose (Figure 7D
and Table S3). Glucose tolerance was improved and insulin
levels were lower in HFD-fed mice treated with the PexRAP
ASO (Figures 7E and 7F).
DISCUSSION
These studies suggest that depletion of FAS in adipose tissue
suppresses HFD-induced obesity. FAS is a minor contributor
to cellular lipid stores with high fat feeding (Aarsland et al.,l Metabolism 16, 189–201, August 8, 2012 ª2012 Elsevier Inc. 195
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Figure 5. Cloning and Characterization of the Terminal Component in the Mammalian Peroxisomal Ether Lipid Synthetic Pathway
(A) The peroxisomal acyl-DHAP pathway of lipid synthesis. FAS, fatty acid synthase; ACS, acyl CoA synthase; G3PDH, glycerol 3-phosphate dehydrogenase;
DHAP, dihydroxyacetone phosphate; DHAPAT, DHAP acyltransferase; FAR1, fatty acyl CoA reductase 1; ADHAPS, alkyl DHAP synthase; ADHAP Reductase,
acyl/alkyl DHAP reductase activity; LPA, lysophosphatidic acid; AGP, 1-O-alkyl glycerol 3-phosphate.
(B) Mouse DHRS7b is homologous to yeast acyl DHAP reductase, Ayr1p. TMD, transmembrane domain; Adh_short, short chain dehydrogenase/reductase
domain.
(C) PexRAP (peroxisomal reductase activating PPARg, detected using anti-DHRS7b antibody) is enriched in peroxisomal fractions isolated from 3T3-L1
adipocytes. S, supernatant; P, pellet after sedimentation.
(D) Pex19 coimmunoprecipitates with Myc-tagged PexRAP. WCL, whole cell lysates.
(E) Pex19 interacts with PexRAP in GST pull-down experiments using 3T3-L1 adipocytes.
(F) RT-PCR analysis of PexRAP expression with PexRAP knockdown in MEFs. **p = 0.0084.
(G) Mass spectrometric analyses of [M+H]+ ions of GPC lipids in MEFs after PexRAP knockdown. Quantification of the 1-O-alkyl ether GPC lipid peak atm/z 746
[M+H]+ (identical to the lithium adduct at m/z 752 in Figure 4C) is shown in the inset. **p = 0.0009.
(H) Mouse tissue distribution of PexRAP protein by western blotting.
(I) Protein abundances of PexRAP and FAS increase prior to increases in C/EBPa and aP2 during differentiation of 3T3-L1 adipocytes. Error bars in (F) and (G)
(inset) represent SEM.
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Lipogenesis and Adipose Programming1996; Letexier et al., 2003; McDevitt et al., 2001); HFD feeding
decreases FAS expression (Coupe et al., 1990; Kersten, 2001).
Thus, it is unlikely that the reduced adiposity observed in the
HFD-fed FASKOF mice was due to the inability to synthesize
fatty acids per se. Rather, our results suggest that inhibiting
a lipogenic pathway initiated by FAS increases thermogenesis
and reduces activation of PPARg. Increased energy expenditure
comes not from effects on classic BAT but instead by inducing196 Cell Metabolism 16, 189–201, August 8, 2012 ª2012 Elsevier Incthe formation of brown fat-like (‘‘brite’’) cells in subcutaneous
adipose tissue (Seale et al., 2011).
In addition to inducing brown fat-like cells in subcutaneous
fat, FAS deletion decreased PPARg transcriptional activity. It is
possible that these transcriptional effects are unrelated or only
partially related to the phenotype of resistance to diet-induced
obesity caused by increased brite cells. PPARg agonism can
induce UCP1 gene expression and produce small adipocytes in.
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Figure 6. PexRAP Is Required for Adipogenesis and PPARg Activation
(A) Nile red staining of 3T3-L1 adipocytes treated with control or PexRAP shRNA in the presence or absence of rosiglitazone.
(B) Triglyceride content for the cells of (A). **p = 0.0066 versus control, #p = 0.0071 versus PexRAP shRNA vehicle. N = 3/condition.
(C) RT-PCR analysis of gene expression following PexRAP or DHAPAT knockdown. P versus control: DHAPAT, *0.0278, **0.007; PexRAP, *0.040; aP2, **0.0060
for PexRAP shRNA and 0.0058 for DHAPAT shRNA; C/EBPa, *0.0160 for PexRAP shRNA and 0.0165 for DHAPAT shRNA; LPL, **0.0014, *0.0450; CD36, *0.0113
for PexRAP shRNA and 0.0132 for DHAPAT shRNA. N = 3–5/condition.
(D) Rosiglitazone treatment rescues the effect of PexRAP or DHAPAT knockdown on PPARg target gene expression. 3T3-L1 cells infected with lentivirus ex-
pressing control, PexRAP, or DHAPAT shRNA were induced to differentiate into adipocytes and then treated with 2.5 mM rosiglitazone. Expression of PPARg
target genes was analyzed by quantitative RT-PCR. For aP2, exact p values from left to right = 0.0038, 0.0119, 0.0024, 0.0032. For CD36, p values = 0.0022,
0.0015, 0.0110, < 0.0001.
Error bars in (B)–(D) represent SEM.
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Lipogenesis and Adipose ProgrammingWAT (de Souza et al., 2001; Fukui et al., 2000; Tiraby et al., 2003),
similar to the FASKOF mouse phenotype, and yet FASKOF mice
have decreased PPARg activation. However, pharmacologic
agonism of PPARg promotes adiposity, while FASKOF mice
have less adiposity. Effects on PPARa with FAS deletion could
provide a plausible explanation. PPARa and its targets are
induced in FASKOF adipose tissue (Figure 2D). PPARa inhibition
decreases induction of the PPARa target gene ACO with FAS
knockdown in 3T3-L1 cells (Figure S3D). PPARa agonism can
also induce UCP1 gene expression (Barbera et al., 2001) asCelwell as decrease adipocyte size (Tsuchida et al., 2005), and the
acute effects of PPARa activation on UCP1 gene expression
may exceed those of PPARg (Pedraza et al., 2001). Decreased
PPARg transcriptional activity could reflect the lack of an FAS-
associated lipid ligand, allowing increased PPARa activity and
induction of UCP1. In support of this notion, induction of UCP1
and the development of brown fat-like cells by FNDC5 (cleaved
to form irisin) occurs in part throughPPARa (Bostro¨met al., 2012).
Our data point to a pathway (Figure 7G, left) in which lipids
synthesized by FAS serve as substrate for PexRAP, whichl Metabolism 16, 189–201, August 8, 2012 ª2012 Elsevier Inc. 197
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Figure 7. Knockdown of PexRAP in Mice Alters Body Composition and Metabolism
(A) PexRAP knockdown using antisense oligonucleotides (ASOs) in Hepa1-6 cells.
(B) Western blot analysis using epididymal WAT of C57BL/6J mice treated intraperitoneally with the indicated doses of control or PexRAP ASO twice a week for
3 weeks.
(C) RT-PCR analysis of epididymal WAT expression following ASO treatment. P versus control: PexRAP **0.0078; PPARg **0.0051; CD36 *0.0420; LPL **0.0030.
N = 4/condition.
(D) Body composition byMRI following 4weeks of HFD feeding (baseline) and after 3.5 weeks of ASO treatment while still eating aHFD. **p = 0.0098 for fat, 0.0071
for lean. N = 4/condition.
(E) Glucose tolerance testing in HFD-fed mice following ASO treatment. *p = 0.0220 at 15 min and 0.0434 at 120 min. **p = 0.0019.
(F) Insulin levels at the 30 min point from (E). *p = 0.0363.
(G) Models of PPARg and PPARa gene expression in WT and FAS-deficient adipocytes. Error bars in (C)–(F) represent SEM.
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PPARg ligands. Disruption of FAS (Figure 7G, right) decreases
these ether lipids, altering the coactivator milieu to favor
PPARa-dependent gene expression.
Several lines of evidence support the concept that a lipogenic
pathway localized to peroxisomes is important for endogenous
activation of PPARg. The PPAR family was named because of
the ability to be activated by agents that increase the number
of peroxisomes (Dreyer et al., 1992; Issemann and Green,
1990). The number of peroxisomes is dramatically increased
during differentiation of 3T3-L1 adipocytes (Novikoff and Novik-
off, 1982; Novikoff et al., 1980), a PPARg-dependent process.
Consistent with our observation that PexRAP expression is198 Cell Metabolism 16, 189–201, August 8, 2012 ª2012 Elsevier Incinduced during adipogenesis, previous studies suggest that
the activities of various enzymes in the peroxisomal ether lipid
synthetic pathway increase during differentiation of 3T3-L1 adi-
pocytes (Hajra et al., 2000).
There is precedent for PPARg activation by alkyl ether lipids.
Azelaoyl PAF (1-O-hexadecyl-2-O-(9-carboxyoctanoyl)-sn-glyc-
eryl-3-phosphocholine), reported to be equipotent to rosiglita-
zone (Davies et al., 2001), and 1-O-alkyl glycerol 3-phosphate
(McIntyre et al., 2003; Tsukahara et al., 2006), synthesized
directly by PexRAP (see Figure 5A), are thought to be PPARg
ligands. Because PPARg has a capacious ligand binding pocket
(Schupp and Lazar, 2010), it is possible that instead of a single
authentic endogenous ligand, multiple lipids are recruited to.
Cell Metabolism
Lipogenesis and Adipose Programmingthe receptor depending on the physiological context, with vari-
able effects on transcriptional activity (Lodhi et al., 2011; Schupp
and Lazar, 2010).
ASO-mediated inhibition of PexRAP decreased adiposity and
improved glucose metabolism, probably by activating thermo-
genesis in subcutaneous WAT. In studies to be reported else-
where, we have observed that PexRAP deficiency in adipose
tissue achieved by crossing adiponectin-Cre mice with floxed
PexRAP animals robustly induces UCP1 expression in subcuta-
neous but not epididymal WAT.
Adipose-specific knockout of PPARg in mice has yielded
conflicting results: one group reported lipodystrophy and insulin
resistance (He et al., 2003), while another found enhanced insu-
lin sensitivity (Jones et al., 2005). Certain human PPARg muta-
tions cause lipodystrophy and insulin resistance, likely through
a dominant-negative effect to disrupt interaction with coactiva-
tors (Agostini et al., 2006). In our studies, neither ASO-mediated
PexRAP knockdown in mice nor Cre-mediated adipose-specific
FAS knockout in mice produced lipodystrophy. Both decreased
adiposity and improved glucose metabolism. PPARg haploin-
sufficiency in mice (Kubota et al., 1999; Miles et al., 2000) also
decreases adiposity and increases insulin sensitivity, but this
genetic effect is not limited to adipose tissue. A Pro12Ala
PPARg mutation in mice (Heikkinen et al., 2009) and humans
(Huguenin and Rosa, 2010) decreases (but does not abolish)
PPARg transcriptional activity and results in decreased adiposity
and increased insulin sensitivity, although this mutation is not
adipose-specific.
Inhibiting FAS or the peroxisomal enzyme PexRAP in adipose
tissue alters body composition and improves glucose metabo-
lism in the setting of a high fat diet. Both represent attractive
targets for novel diabetes and obesity therapies.
EXPERIMENTAL PROCEDURES
Animals
Mice with a floxed FAS locus (FASlox/lox) (Chakravarthy et al., 2005) were
crossed with transgenic mice (a gift from Evan Rosen, BI Deaconess) express-
ing Cre recombinase under the control of the adiponectin promoter (Eguchi
et al., 2011) to obtain FASKOF mice that were studied after backcrossing
R7 times with pure C57BL/6J mice. Genotyping was performed using previ-
ously described primer sets and diets included Purina 4043 control chow,
Harlan Teklad TD 88137 high fat diet, and Harlan Teklad TD03314 high carbo-
hydrate/zero fat diet. Unless indicated otherwise, male FASKOF mice and
control littermates at 8–12 weeks of age were used for experiments. For
antisense oligonucleotide studies, 8-week-old C57BL/6J mice were used.
All protocols were approved by the Washington University Animal Studies
Committee.
Cell Culture
Primary mouse embryonic fibroblasts (MEFs) were isolated at 13.5 days post
conception from FASlox/lox embryos as previously described (Razani et al.,
2001) andmaintained in DMEM+10% FBS. MEFs were differentiated to adipo-
cytes by treatment with 1 mM dexamethasone, 5 mg/ml insulin and 0.5 mM
IBMX for 14 days, followed by supplemental 5 mg/ml insulin alone for an addi-
tional 4 days. 3T3-L1 cells were maintained in DMEM+10% NCS and differen-
tiated to adipocytes as previously described (Lodhi et al., 2007). CV-1, HEK293
and HEK293T cells were maintained in DMEM+10% FBS.
Lentiviral shRNA-Mediated Knockdown
Plasmids encoding shRNA for mouse FAS (TRCN0000075703), PexRAP
(TRCN0000181732 and 0000198546), and DHAPAT (TRCN0000193539)
were obtained from Open Biosystems (Huntsville, AL). Packaging vectorCelpsPAX2 (12260), envelope vector pMD2.G (12259), and scrambled shRNA
plasmid (1864) were obtained from Addgene. 293T cells in 10 cm dishes
were transfected using Fugene 6 with 2.66 mg psPAX2, 0.75 mg pMD2.G,
and 3 mg shRNA plasmid. After 48 hr, media were collected, filtered using
0.45 um syringe filters, and used to treat cells. After 36 hr, cells were selected
with puromycin and knockdown was assessed after an additional 48 hr.
Identification of Alkyl Ether GPC Lipids Associated with PPARg
The strategy for detecting endogenous lipids associated with PPARg involved
adenovirus-mediated expression of FLAG-tagged PPARg or GFP (as control)
in cells induced to differentiate into adipocytes. Nuclear fractions, prepared
from cell lysates and subjected to hypotonic lysis as described (Chakravarthy
et al., 2009), were incubated with an antibody recognizing the FLAG epitope to
capture the PPARg construct and any associated lipids under conditions (no
detergent or high salt elution buffers) unlikely to disrupt potential ligand/
nuclear factor interaction.
Affinity matrix eluates (with equal protein content) of nuclear fractions from
cells treated with Ad-GFP (as a control) or Ad-PPARg were subjected to lipid
extraction. These extracts were mixed with an internal standard [(14:0/14:0)-
GPC] and analyzed as [M+Li]+, [M+H]+, or [M+Na]+ ions by positive ion
ESI/MS or as [M+CH3CO2]
- ions by negative ion ESI/MS (Hsu and Turk,
2007; Hsu et al., 2003). To determine the identity of the lithiated lipid species
of m/z 752, we performed multigenerational tandem MS on a linear ion
trap instrument. Collisionally activated dissociation (CAD) was employed to
deduce structures of R1 and R2 substituents. Additional details are provided
in Figure S3.
GST-PexRAP Pull-Down Assays
3T3-L1 adipocytes were lysed using a buffer containing 50 mM HEPES
(pH 7.4), 4 mM EDTA, 2 mM EGTA, 2 mM sodium pyrophosphate, 1% Triton
X-100, 10 mMNaF, and protease inhibitors. Lysates were mixed with an equal
volume of the same buffer lacking Triton X-100, then 5 mg of GST or GST-
PexRAP was added and samples were rocked at 4C. After 2 hr, samples
were centrifuged at 2500 3 g for 1 min, beads were washed 5 times with
1 ml of the lysis buffer containing Triton X-100, then 2X SDS-PAGE sample
buffer was added and samples were subjected to SDS-PAGE.
Antisense Oligonucleotides
ASOs were synthesized by TriLink Biotechnologies (San Diego, CA). The first 5
and last 5 nucleotides were substituted with 20 O-methyl RNA bases; all of the
bases had phosphorothioate linkages. The PexRAP ASO (RNA bases under-
lined) is: 50 GGUUGGTGTGTCTGTCCCUG 30. The control oligonucleotide is:
50 CCUUCCCTGAAGGTTCCUCC 30. Both were purified by anion exchange
HPLC, lyophilized, reconstituted with 0.9% normal saline, and then injected
intraperitoneally.
Statistical Analysis
Data are expressed as mean ± SEM. Comparisons between two groups were
performed using an unpaired, two-tailed t test. ANOVAwas used for more than
two groups and post testing was performed using Tukey’s post test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, three tables, Supplemental
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